Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2019

View Archived Issues

Downstream drugging improves RAS inhibition

Immune cell interaction key to better dengue vaccines

FDA accepts IND application for MT-8633

New zebrafish model allows screening for treatments for acute hyperuricemia

AGS signs research agreement with NIAID for experimental HIV/AIDS cell and gene therapy

PNP Therapeutics initiates phase I/II study of Ad/PNP-F-araAMP in local head and neck cancer

Bridge Biotherapeutics recruiting participants in first-in-human study of BBT-877

Huntingtin implicated in fragile X syndrome

Massachusetts Institute of Technology patents new AR antagonists

Lundbeck presents compounds for schizophrenia

Patient enrollment is ongoing in Akros Pharma's phase II study of JTE-451

Crinetics Pharmaceuticals discloses new somatostatin SST2 receptor agonists

Italian researchers synthesize new molecules targeting KCNH2 and ITGB1

Dual complement inhibition by CRIg/FH shows renoprotective effect in ischemia reperfusion injury

Codiak Biosciences describes new nanovesicles for inflammation-related conditions

NAPE-PLD, key regulator of intestinal fat absorption, liver lipid deposition and energy homeostasis

Innovent and Chipscreen collaborate to study chidamide, sintilimab and IBI-305 in colorectal cancer

Grant to support phase II development of AKL's APPA for osteoarthritis

First patient-derived xenograft models of primary central nervous system lymphomas

Docking library to include over 1 billion lead-like compounds for drug discovery

Biofabri initiates phase IIa study of TB vaccine candidate MTBVAC in South African neonates

Bionomics reports pharmacometric analysis of phase II RESTORE trial of BNC-210 for PTSD

Amgen begins first-in-human study of BiTE antibody AMG-160 in metastatic CRPC

New loci identified for type 2 diabetes in Japanese individuals

GlaxoSmithKline describes discovery of sulforaphane analogues for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...